Estrogen receptor expression is a common feature of ovarian borderline tumors - PubMed (original) (raw)

Case Reports

Estrogen receptor expression is a common feature of ovarian borderline tumors

G M Abu-Jawdeh et al. Gynecol Oncol. 1996 Feb.

Abstract

Purpose: The presence of estrogen receptor (ER) and its therapeutic significance in ovarian borderline tumors (OBT) have not been established. We recently observed a response to tamoxifen therapy given empirically to a patient with unresectable, recurrent serous borderline tumor (SBT). In view of this observation the present study was undertaken to assess ER expression in 51 cases of OBT.

Materials and methods: ER expression was determined retrospectively, using an immunohistochemical method on formalin-fixed, paraffin-embedded specimens, from 35 cases of SBTs, 6 cases of mucinous mullerian (MMBT), and 10 cases of mucinous intestinal borderline tumors (MIBT). ER was considered positive if > 5% of tumor epithelial cell nuclei were immunostained. Both SBTs and mucinous borderline tumors (MBTs) were included to determine the influence of histologic type on ER expression.

Results: The patients ranged in age from 25 to 77 years (median 43 years for SBTs, 36 years for MMBTs, and 37 years for MIBTs). The stage distribution for the SBTs was stage I in 27 patients (77%), stage II in 4 patients (11.5%), and stage III in 4 patients (11.5%). All patients with MBTs were stage I. ER expression was observed in the majority of cases and correlated with histologic type: 94% (33/35) of SBTs and 100% (6/6) of MMBTs were ER positive compared to 0% (0/10) of MIBTs (P < 0.01). In the SBT category the presence of ER did not correlate significantly with stage or age. In addition, ER was positive in all four SBT implants (including one involved lymph node) and two recurrent SBTs analyzed.

Conclusion: ER expression is a common feature of SBT and MMBT, but not MIBT. The relevance of ER expression in the pathogenesis and treatment of OBTs requires further investigation.

PubMed Disclaimer

Cited by

Conservative treatment of borderline ovarian tumors: a retrospective study.
Văduva CC, Constantinescu C, Ţenovici M, Boldeanu L, Istrate-Ofiţeru AM. Văduva CC, et al. Rom J Morphol Embryol. 2023 Apr-Jun;64(2):143-150. doi: 10.47162/RJME.64.2.03. Rom J Morphol Embryol. 2023. PMID: 37518870 Free PMC article.
Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature.
Wetterwald L, Sarivalasis A, Liapi A, Mathevet P, Achtari C. Wetterwald L, et al. Cancers (Basel). 2023 Jan 31;15(3):890. doi: 10.3390/cancers15030890. Cancers (Basel). 2023. PMID: 36765848 Free PMC article. Review.
Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.
Shanta K, Nakayama K, Hossain MM, Razia S, Ishibashi T, Ishikawa M, Yamashita H, Kanno K, Sato S, Nakayama S, Otsuki Y, Kyo S. Shanta K, et al. Curr Oncol. 2022 Jun 1;29(6):4020-4033. doi: 10.3390/curroncol29060321. Curr Oncol. 2022. PMID: 35735430 Free PMC article.
Borderline ovarian tumor in the pediatric and adolescent population: a clinopathologic analysis of fourteen cases.
Xu M, Wang B, Shi Y. Xu M, et al. Int J Clin Exp Pathol. 2020 May 1;13(5):1053-1059. eCollection 2020. Int J Clin Exp Pathol. 2020. PMID: 32509078 Free PMC article.
Controversies in borderline ovarian tumors.
Seong SJ, Kim DH, Kim MK, Song T. Seong SJ, et al. J Gynecol Oncol. 2015 Oct;26(4):343-9. doi: 10.3802/jgo.2015.26.4.343. Epub 2015 Sep 23. J Gynecol Oncol. 2015. PMID: 26404125 Free PMC article. Review.

Estrogen receptor expression is a common feature of ovarian borderline tumors - PubMed (original) (raw)